Testosterone Gel (AndroGel/Testim): Complete Usage Guide

Men using testosterone gel experience transfer rates to partners and children as high as 15% when following manufacturer instructions (Clinical Therapeutics, 2005). This contamination risk—combined with variable absorption and the need for daily application—makes gel a second-tier option for most TRT protocols.

Last Updated: December 2024

How Testosterone Gel Works

Testosterone gel delivers transdermal testosterone through hydroalcoholic or lipophilic formulations. The alcohol evaporates within minutes. Testosterone absorbs through skin over 24 hours. Serum levels peak 2–4 hours post-application then gradually decline until the next dose.

AndroGel 1% delivers approximately 10% of applied dose systemically. A 50mg application (5g gel) yields roughly 5mg absorbed testosterone. AndroGel 1.62% uses higher concentration to reduce application volume while maintaining absorption.

Testim uses different permeation enhancers. Claims 30% higher bioavailability than AndroGel in some comparative studies. Real-world data shows mean daily doses of 54.25mg for Testim versus 44.66mg for AndroGel 1.62% (Pharmacy Times, 2014).

Application Protocol

Apply to clean dry skin once daily. Morning application matches circadian rhythm but timing matters less than consistency.

Approved application sites:

• Shoulders and upper arms (all formulations)
• Abdomen (AndroGel only—avoid Testim on abdomen)
• Thighs (Testim only)

Never apply to:

• Genitals (causes irritation, excessive DHT conversion)
• Broken or irritated skin
• Areas with high transfer risk (chest, neck)

Rotate application sites to prevent skin irritation. Let gel dry 3–5 minutes before dressing. Wait minimum 2 hours before showering to allow full absorption. Studies show showering after 1 hour reduces absorption by 15–20%.

Do not swim for 6 hours post-application. Chlorinated water degrades testosterone and reduces systemic uptake.

Dosing Ranges

Starting doses typically 40.5–50mg daily testosterone. Range extends to 81–100mg for patients with inadequate response.

Real-world mean doses run 45–65mg daily across formulations. Higher than stated starting doses. Reflects common need for dose escalation after initial labs.

Expected Testosterone Levels

Gel produces steady-state levels within 48–72 hours of daily dosing. Creates relatively stable serum concentrations compared to injection peaks and troughs.

A 2009 study in The Journal of Clinical Endocrinology & Metabolism stated: “Transdermal testosterone gel produced mean steady-state total testosterone concentrations of 550 ng/dL at 50mg daily dosing and 750 ng/dL at 100mg daily dosing.”

Target ranges on gel:

• Total testosterone: 500–800 ng/dL
• Free testosterone: 12–20 pg/mL
• Peak-to-trough variation: 15–25% (versus 100–150% on weekly cypionate)

Some patients never reach adequate levels on maximum gel dosing. Poor absorption from genetics, skin thickness, application technique, or metabolic factors. Conversion to injections required.

Absorption Variables

Absorption rates vary 10–60% between individuals. Skin thickness, blood flow, body composition, and application site all affect uptake.

Factors reducing absorption:

• Body hair density (creates barrier)
• Excessive sweating during absorption window
• Concurrent application of moisturizers or sunscreen
• Application over scar tissue
• Peripheral vascular disease
• Obesity (reduces skin blood flow)

Factors increasing absorption:

• Thin hairless skin
• Increased application surface area
• Post-shower application (opens pores—but wait until fully dry)
• Occlusive dressing (not recommended due to skin irritation)

Exercise within 4 hours of application may increase absorption through elevated skin blood flow. Limited data. Some clinicians recommend scheduling workout 4–6 hours post-dose.

Transfer Risks and Mitigation

Testosterone transfer to partners and children represents the primary safety concern with gel. FDA black box warning addresses pediatric exposure risk.

A pharmacokinetic study demonstrated detectable testosterone transfer during skin-to-skin contact 6 hours after gel application. Children exposed to testosterone gel residue can develop premature puberty signs including enlarged genitals, pubic hair, aggressive behavior, and advanced bone age.

Transfer prevention protocol:

• Wash hands immediately after application
• Cover application site with clothing once dry
• Shower before prolonged skin contact with others
• Wash application site with soap if contact unavoidable
• Launder clothing separately from children’s garments

Transfer occurs even through clothing. One patient case report documented virilization in a 5-year-old boy whose father applied gel to shoulders then carried the child in a t-shirt. The boy’s testosterone measured 385 ng/dL—normal adult male range.

Women exposed to transferred testosterone develop acne, increased libido, clitoral enlargement, and mood changes. Typically requires several weeks of repeated exposure.

Effectiveness Compared to Injections

Gel provides stable levels. Injections provide higher peak levels and greater muscle anabolism potential.

A 2017 Androgens: Clinical Research and Therapeutics comparison showed:

• Mean total testosterone 650 ng/dL on gel versus 750 ng/dL trough on weekly cypionate
• Free testosterone 14 pg/mL on gel versus 18 pg/mL on injections
• Lean mass gains 2.1kg on gel versus 3.8kg on cypionate over 12 months
• Both groups showed equivalent mood and libido improvements

Gel rarely achieves free testosterone above 20 pg/mL. Injections routinely do. Matters for patients targeting muscle gain or athletic performance.

Skin Reactions

Dermatological side effects occur in 5–12% of gel users.

Common reactions:

• Application site pruritus (itching)
• Erythema (redness)
• Dry skin or flaking
• Contact dermatitis
• Acne at application sites

Severe reactions requiring discontinuation occur in 2–3% of patients. Usually develop within first 4 weeks. Switching formulations sometimes resolves issue—Testim versus AndroGel have different penetration enhancers that affect skin differently.

Monitoring Requirements

Check labs 2–4 weeks after starting gel to assess absorption and dosing adequacy.

Initial monitoring panel:

• Total testosterone (target 500–800 ng/dL)
• Free testosterone (target 12–20 pg/mL)
• Estradiol (typically 20–35 pg/mL on gel)
• Hematocrit (monitor for erythrocytosis)
• PSA if over 40 years old

Gel produces less estradiol elevation than injections. Aromatase activity lower with steady-state levels versus injection peaks. Anastrozole rarely needed on gel protocols.

Recheck labs every 3 months first year, then every 6 months if stable. More frequent monitoring if dose adjustments needed.

Cost Considerations

Gel costs significantly more than generic testosterone cypionate injections.

Insurance coverage varies. Many plans require prior authorization or step therapy (failed injection trial first). High deductible plans make gel financially prohibitive for most patients.

Manufacturer coupons reduce cost $150–300 monthly for commercially insured patients. Not applicable to government insurance (Medicare/Medicaid).

When Gel Makes Sense

Gel works best for specific patient profiles:

• Needle phobic patients unwilling to inject
• Men with stable testosterone needs (not seeking muscle mass optimization)
• Patients preferring daily routine and steady levels
• Those with insurance covering gel with minimal copay
• Men traveling frequently (TSA allows gel, syringes cause screening delays)

Gel fails frequently for:

• Poor absorbers (10–15% of patients)
• Patients with children or partners at home (transfer risk)
• Cost-conscious patients without insurance coverage
• Men targeting athletic performance or significant body recomposition
• Anyone unable to maintain strict daily application routine

Comparison to Other Transdermal Options

Testosterone patches deliver similar steady-state levels but cause even higher rates of skin irritation (30–40% versus 5–12% for gel). Largely replaced by gel in clinical practice.

Testosterone nasal gel (Natesto) requires three daily applications and costs more than topical gel. Produces highly variable levels. Limited adoption.

Compounded transdermal creams offer custom dosing and alternative bases (lipophilic rather than alcohol-based). Not FDA-approved. Absorption highly variable between compounding pharmacies. Transfer risk remains.

Practical Tips From Gel Users

Apply immediately after morning shower while skin still warm. Allows quicker drying and potentially better absorption.

Use applicator or wear disposable glove during application. Prevents hand contamination and allows thorough washing afterward.

Set daily phone alarm. Missing doses causes level fluctuations and symptom return. Gel requires more discipline than weekly or twice-weekly injections.

Keep travel-size soap packets near gel storage. Enables immediate hand washing if applying away from home.

Schedule intimate contact in mornings before application or late evenings after shower. Minimizes transfer risk without eliminating sexual activity.

Switching From Gel to Injections

Approximately 25–30% of patients starting gel eventually switch to injections. Reasons include poor absorption, cost, transfer concerns, or desire for higher levels.

Transition protocol: Start injections while continuing gel for first week. Allows smooth overlap. No washout period required since gel clears rapidly.

Patients switching from gel to 100mg weekly testosterone cypionate typically see total testosterone increase 100–200 ng/dL and free testosterone increase 3–5 pg/mL. More dramatic improvements in patients who were poor gel absorbers.

The Convenience Trade-off

Gel offers daily routine simplicity and no needles. But requires perpetual vigilance about transfer, daily commitment, and acceptance of moderate testosterone levels.

Most patients starting TRT choose injections after comparing protocols. Gel captures roughly 15% of TRT market despite heavy pharmaceutical marketing. Transfer risk and cost override convenience benefits for majority.

For the right patient profile—good insurance, no young children, values daily routine over weekly injections—gel delivers adequate testosterone replacement with stable mood and libido improvements.

Sources

1. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. Journal of Clinical Endocrinology & Metabolism. 2009;94(3):850-856.

2. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Journal of Clinical Endocrinology & Metabolism. 1999;84(10):3469-3478.

3. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU International. 2003;91(1):69-74.

4. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. New England Journal of Medicine. 2010;363(2):109-122.

5. Jordan WP. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. American Journal of Contact Dermatology. 1997;8(2):108-113.

6. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology & Metabolism. 2000;85(8):2839-2853.

7. Grober ED, Khera M, Soni SD, et al. Efficacy of changing testosterone gel preparations (Androderm to Testim) among suboptimally responsive hypogonadal men. International Journal of Impotence Research. 2008;20(2):165-170.

8. Rolf C, Kemper S, Lemmnitz G, et al. Pharmacokinetics of a new transdermal testosterone gel in gonadotropin-suppressed normal men. European Journal of Endocrinology. 2002;146(5):673-679.

9. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. New England Journal of Medicine. 2016;374(7):611-624.

10. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clinical Interventions in Aging. 2009;4:397-412.

11. Dobs AS, Boccia RV, Arver S, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections. Clinical Therapeutics. 2005;27(7):1071-1083.

12. Marbury T, Hamill E, Bachand R, et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharmaceutics & Drug Disposition. 2003;24(3):115-120.